SCHEDULE: FMR LLC Discloses 9.7% Stake in Veracyte Inc.

FMR LLC, along with Abigail P. Johnson, has reported a beneficial ownership of 9.7% in Veracyte Inc. as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating their beneficial ownership of Veracyte Inc. common stock.
• As of March 31, 2026, the aggregate amount beneficially owned is 7,703,848.74 shares.
• This represents 9.7% of the class of securities.
• FMR LLC holds sole voting power for 7,695,967.00 shares and sole dispositive power for 7,703,848.74 shares.
• Abigail P. Johnson is identified as a reporting person, with shared voting power of 0.00 and sole dispositive power of 7,703,848.74 shares.
• The filing indicates that other persons have the right to receive or direct the sale of dividends, but no single other person's interest exceeds five percent.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on existing ownership stakes rather than providing new operational or financial information that would indicate a change in sentiment.

Positives

• Significant institutional ownership by FMR LLC, suggesting confidence in Veracyte Inc.'s long-term prospects.
• Clear disclosure of beneficial ownership, providing transparency to the market.

Negatives

• The filing does not contain financial performance data or operational updates, limiting the assessment of the company's current health.

Risks

• The filing does not explicitly mention any risks associated with Veracyte Inc. or the reporting persons' holdings.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Veracyte Inc.'s future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for large institutional investors like FMR LLC, indicating significant holdings in publicly traded companies. This filing confirms FMR LLC's substantial investment in Veracyte Inc., a company operating in the diagnostics and life sciences sector.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership, potentially influencing market perception and trading activity.
• Management: Confirmation of a substantial investor base, which can be a positive signal for strategic planning and future capital needs.
• Competitors: Awareness of FMR LLC's significant position in Veracyte Inc. may inform competitive strategies within the diagnostics sector.

Next Steps

• Continue to monitor future filings from FMR LLC and Veracyte Inc. for any changes in ownership or operational updates.

Key Dates

Keywords

Veracyte Inc., FMR LLC, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Abigail P. Johnson